Biosimilar Development News

  1. Psoriasis Treatments To Become Cheaper As Biosimilars Compete In $5B U.S. Psoriasis Drugs Market – New Study By iData Research
    6/20/2018

    A new study by iData Research estimates that there are nearly 150,000 new cases of psoriasis (PsO) every year in the United States, affecting 2.2% of the population. Approximately 80% of those affected have mild-to-moderate psoriasis, while 20% have moderate-to-severe psoriasis, which is often treated with immunology drugs.

  2. Registration Opens For The 9th Annual Biosimilars And Biobetters 2018 Conference
    6/19/2018

    SMi Group is proud to announce the return of the 9th annual Biosimilars and Biobetters conference, taking place on the 26th and 27th September 2018 in London, UK. Registration for the event is now open and the newly released brochure is available to download from the event website.

  3. Celltrion Completes Resubmission To FDA For Proposed Trastuzumab Biosimilar
    6/18/2018

    Celltrion has made a resubmission to the FDA (U.S. Food and Drug Administration) to obtain its marketing approval for CT-P6, a proposed mAb biosimilar to Herceptin (trastuzumab).

  4. Sandoz Presents New Long-Term And Switching Data For Biosimilars Zessly® (Infliximab) And Erelzi® (Etanercept) In Rheumatoid Arthritis
    6/15/2018

    Sandoz, a Novartis division and the pioneer and global leader in biosimilars, today announced the presentation of two long-term, Phase III studies: one each for biosimilar Zessly® (infliximab) and biosimilar Erelzi® (etanercept).

  5. Samsung Bioepis And Biogen Announce Pooled Analysis Results Of Anti-TNF Biosimilars BENEPALI (etanercept), FLIXABI (infliximab), And IMRALDI (adalimumab) At EULAR 2018
    6/13/2018

    Samsung Bioepis Co., Ltd. and Biogen recently announced pooled analysis results of three anti-tumor necrosis factor (anti-TNF) biosimilars – BENEPALI (SB4, etanercept biosimilar), FLIXABI (SB2, infliximab biosimilar), and IMRALDI (SB5, adalimumab biosimilar) – which will be presented at the Annual European Congress of Rheumatology (EULAR 2018) held June 13–16 in Amsterdam, Netherlands.

  6. Celltrion Healthcare Showcases Promising Preliminary Results For New Subcutaneous Formulation Of CT-P13 (Biosimilar Infliximab) In Patients With Rheumatoid Arthritis
    6/12/2018

    New data presented at the Annual European Congress of Rheumatology (EULAR 2018) show that the subcutaneous (SC) formulation of CT-P13 is comparable in terms of efficacy and safety with the intravenous (IV) formulation of CT-P13 for the treatment of patients with rheumatoid arthritis (RA) up to week 30.

  7. ACON Investments And Humus Capital Acquire Biosidus
    6/7/2018

    ACON Investments ("ACON") announced today that affiliates of ACON Latin America Opportunities Fund IV, L.P., in partnership with Humus Capital Partners ("HCP"), a private equity firm based in Argentina, have acquired a majority equity interest in Biosidus S.A. and Biosidus Farma S.A. (collectively, "Biosidus" or the "Company"), Argentina's largest manufacturer and distributor of biosimilar pharmaceuticals with exports worldwide to more than 25 countries across four continents.

  8. New Study: Patients, Employers And Taxpayers Could Save Significantly If Barriers To Biosimilars Removed
    6/6/2018

    A new study released today by the Pacific Research Institute found that, by removing barriers holding back the increased use of biosimilars, savings could be significant. In a case study of infliximab, used to treat rheumatoid arthritis, Crohn's disease, and other illnesses, reforms could realize an annual savings of between $412 million and $465 million

  9. New Subcutaneous Formulation Of Celltrion Healthcare’s CT-P13 (Biosimilar Infliximab) Shows Positive Results For The Treatment Of Active Crohn’s Disease In Data Presented At Digestive Disease Week 2018
    6/5/2018

    Celltrion Healthcare recently presented new research at Digestive Disease Week (DDW) 2018, that shows the efficacy and safety of the CT-P13 subcutaneous (SC) formulation is comparable to the CT-P13 intravenous (IV) formulation up to week 30 in patients with active Crohn’s disease (CD).

  10. Celltrion Launches Bio CDMO Business For The Development Of New Drugs
    6/5/2018

    Celltrion made an announcement that it will launch Bio CDMO (Contract Development and Manufacturing) business, in a bid to pursue open innovation for development of new drugs, at the 2018 BIO International Convention, the world’s premier life sciences event being held in Boston, June 4-7.